Koensgen D[Author] - Search Results

Year	Number of Results
2003	2
2006	1
2007	6
2008	4
2009	5
2010	4
2011	2
2013	1
2014	1
2015	2
2016	4
2017	5
2018	3
2022	1
2023	1

1

Jump in the fire--heat shock proteins and their impact on ovarian cancer therapy.

Stope MB, Koensgen D, Burchardt M, Concin N, Zygmunt M, Mustea A. Stope MB, et al. Among authors: koensgen d. Crit Rev Oncol Hematol. 2016 Jan;97:152-6. doi: 10.1016/j.critrevonc.2015.08.008. Epub 2015 Aug 13. Crit Rev Oncol Hematol. 2016. PMID: 26318096 Review.

2

The future therapy of endometrial cancer: microRNA's functionality, capability, and putative clinical application.

Stope MB, Koensgen D, Weimer J, Paditz M, Burchardt M, Bauerschlag D, Mustea A. Stope MB, et al. Among authors: koensgen d. Arch Gynecol Obstet. 2016 Nov;294(5):889-895. doi: 10.1007/s00404-016-4194-7. Epub 2016 Sep 14. Arch Gynecol Obstet. 2016. PMID: 27637583 Review.

3

New aspects of adjuvant therapy in endometrial cancer: current standards and future directions.

Sehouli J, Koensgen D, Oskay-Ozcelik G, Mustea A. Sehouli J, et al. Among authors: koensgen d. Crit Rev Oncol Hematol. 2008 Sep;67(3):204-12. doi: 10.1016/j.critrevonc.2008.02.011. Epub 2008 Apr 14. Crit Rev Oncol Hematol. 2008. PMID: 18407513 Review.

4

Evaluation of the Diagnostic Potential of Circulating MicroRNAs miR-1 and miR-21 in Patients With Ovarian Cancer.

Ralser DJ, Condic M, Egger E, Koensgen D, Mustea A, Stope MB. Ralser DJ, et al. Among authors: koensgen d. Anticancer Res. 2022 Dec;42(12):5839-5845. doi: 10.21873/anticanres.16092. Anticancer Res. 2022. PMID: 36456138

5

Polymorphism of the IL-8 gene and the risk of ovarian cancer.

Koensgen D, Bruennert D, Ungureanu S, Sofroni D, Braicu EI, Sehouli J, Sümnig A, Delogu S, Zygmunt M, Goyal P, Evert M, Olek S, Biebler KE, Mustea A. Koensgen D, et al. Cytokine. 2015 Feb;71(2):334-8. doi: 10.1016/j.cyto.2014.07.254. Epub 2014 Aug 21. Cytokine. 2015. PMID: 25151495

6

Expression and localization of e-cadherin in epithelial ovarian cancer.

Koensgen D, Freitag C, Klaman I, Dahl E, Mustea A, Chekerov R, Braicu I, Lichtenegger W, Sehouli J. Koensgen D, et al. Anticancer Res. 2010 Jul;30(7):2525-30. Anticancer Res. 2010. PMID: 20682978

7

Evolving treatment landscape of advanced endometrial cancer - A current perspective from a German tertiary referral center for gynecological oncology.

Ralser DJ, Condic M, Otten LA, Koensgen D, Stope MB, Egger EK, Mustea A. Ralser DJ, et al. Among authors: koensgen d. Eur J Obstet Gynecol Reprod Biol. 2023 Jan 7;282:61-63. doi: 10.1016/j.ejogrb.2023.01.008. Online ahead of print. Eur J Obstet Gynecol Reprod Biol. 2023. PMID: 36640696 Free article. No abstract available.

8

The Tumor Suppressor MicroRNA-1 Exhibits Restricted Inhibition of Proliferation of Ovarian Cancer Cells.

Stope MB, Hettenbach D, Kaul A, Paditz M, Diesing K, Burchardt M, Zygmunt M, Mustea A, Koensgen D. Stope MB, et al. Among authors: koensgen d. Anticancer Res. 2016 Jul;36(7):3329-34. Anticancer Res. 2016. PMID: 27354590

9

Drug-induced Modulation of Heat Shock Protein HSPB1 in an Ovarian Cancer Cell Model.

Stope MB, Wiegank L, Weiss M, Diesing K, Koensgen D, Burchardt M, Zygmunt M, Mustea A. Stope MB, et al. Among authors: koensgen d. Anticancer Res. 2016 Jul;36(7):3321-7. Anticancer Res. 2016. PMID: 27354589

10

Functionality of the Tumor Suppressor microRNA-1 in Malignant Tissue and Cell Line Cells of Uterine Leiomyosarcoma.

Stope MB, Cernat V, Kaul A, Diesing K, Koensgen D, Burchardt M, Mustea A. Stope MB, et al. Among authors: koensgen d. Anticancer Res. 2018 Mar;38(3):1547-1550. doi: 10.21873/anticanres.12383. Anticancer Res. 2018. PMID: 29491084

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results